<DOC>
	<DOCNO>NCT00415207</DOCNO>
	<brief_summary>This study try determine whether certain gene responsible huge variation toxicity effect observe patient treat paclitaxel ( chemotherapeutic drug ) . Specifically study retrospectively patient participate clinical trial close . All patient ovarian cancer receive paclitaxel/carboplatin chemotherapy primary surgery .</brief_summary>
	<brief_title>Pharmacogenomics Paclitaxel Ovarian Cancer</brief_title>
	<detailed_description>Paclitaxel antineoplastic drug use treatment ovarian cancer . The effect toxicity unpredictable individual patient . Paclitaxel remove ( eliminate ) organism oxidation . CYP2C8 enzyme mainly responsible . P-glycoprotein ( Pgp ) efflux transport protein natural human organism . Pgp responsible excretion drug via bile kidney think play role chemotherapy resistance . Paclitaxel substrate Pgp . Single nucleotide polymorphism possible cause variation CYP2C8 Pgp expression/function . We study possible role genetic variation predictor paclitaxel toxicity effect possible implication individual dosing future . We use tissue patient participate one two clinical trial close inclusion . Genotypic data tissue correlate toxicity survival data draw research database . We expect able find &gt; 300 available case study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Patients enrol `` TC/TEC '' Denmark , Sweden Norway Patients enrol `` OVAR9 '' Denmark , Sweden Norway</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>CYP2C8</keyword>
	<keyword>MDR1</keyword>
	<keyword>Pharmacogenetics</keyword>
	<keyword>Paclitaxel</keyword>
</DOC>